Table 1.
Patient characteristics
| Age at time of diagnosis (n = 39) | 65.2 years (min 32 – max 86) | |
| Body Mass Index at time of diagnosis (n = 36) | 31 (17–43) | |
| Parity (median, range) | 2 (0–5) | |
| Reproductive history | Spontaneuos abortion (median, range) | 0 (0–2) |
| Menopausal status | Pre-menopausal | 5 (12.8%) |
| Post-menopausal | 34 (87.2%) | |
| CA125 (n = 32) | 136.3 (min 2 – max 2084) | |
| Tumour marker levels | CEA (n = 32) | 3.4 (min 2 – max 17) |
| IA | 21 (54%) | |
| IB | 8 (20.5%) | |
| II | 1 (2.6%) | |
| FIGO stage (n = 39) | IIIA | 2 (5.1%) |
| IIIB | 2 (5.1%) | |
| IIIC1 | 3 (7.7%) | |
| IIIC2 | 1 (2.6%) | |
| IV | 1 (2.6%) | |
| Tumour type | Type 1 | 36 (92.3%) |
| Type 2 | 3 (7.7 %) | |
| POLEmut | 1 (2.6%) | |
| Molecular tumour | MMRd | 13 (33.3%) |
| classification | NSMP | 22 (56.4%) |
| p53abn | 3 (7.7%) | |
MMRd = mismatch repair deficient tumour; NSMP = non-specific molecular profile tumour; p53abn = p53 expression abnormal tumour; POLE = DNA polymerase-epsilon; POLEmut = POLE ultramutated tumour